# A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation

> **NCT02988674** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 139 (actual)

## Conditions studied

- Spondylarthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis (AS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02988674
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2019-10-16
- **Final completion:** 2019-10-16
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02988674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02988674, "A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02988674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*